Posted by Michael Wonder on 16 Sep 2017
Proposal to fund zoster vaccine
15 September 2017 - PHARMAC is seeking feedback on a proposal to fund the zoster vaccine (Zostavax) for the prevention of shingles (herpes zoster) from 1 April 2018 through a provisional agreement with Merck Sharpe & Dohme Limited.
PHARMAC is proposing to list the zoster vaccine in Section B and in Part II of Section H of the Pharmaceutical Schedule for people aged 65 years and with a 2-year catch up programme for people aged between 66 and 80 years inclusive.
